"These clinical results are extremely encouraging and further validate both the CD19 target and the overall eACT approach," said Keith Nolop, MD, Chief Medical Officer of Kite Pharma. "These patients have aggressive disease that is resistant to chemotherapy, and they have no viable treatment options other than a clinical trial. Both the high overall response rate and the durability of the responses are noteworthy."Arie Belldegrun, MD, Founder and Executive Chairman of the Board of Kite Pharma, added, "Our collaboration with the NCI has been highly productive and rewarding. Given the dramatic responses achieved so far, Kite is fully committed to rapidly advance the clinical development of the CAR technology for multiple indications. We look forward to bringing this promising therapy to patients with advanced cancer."
Kite Pharma's Lead Program With The National Cancer Institute (NCI) Demonstrates Positive Results In Patients With Aggressive Non-Hodgkin's Lymphoma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.